Immunotherapy in general and checkpoint inhibitors in particular have created a path for the treatment of lung cancer that has the potential to lead to long-term survival, even for patients at the most advanced stages.

There is a concerted effort underway at NewYork-Presbyterian/Weill Cornell Medical Center to pursue every opportunity to slow growth, even when a cancer cannot be eradicated.